

Securities Code: 4523

FY 2015 (Ending March 31, 2016)
Second Quarter Financial Results

Reference Data

October 30, 2015

Eisai Co., Ltd.

For Inquiries:

Public Relations: TEL +81-(0)3-3817-5120

Investor Relations: TEL +81-(0)3-3817-3016

<http://www.eisai.com/>

Forward-Looking Statements and Risk Factors

Materials and information provided in this financial disclosure may contain "forward-looking statements" based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations.

Risks that may cause significant fluctuations in the consolidated results of the Eisai Group or have a material effect on investment decisions are described below. These are risk factors that have been identified and assessed as of the disclosure date of the Financial Report.

Risk factors associated with our business include, but are not limited to, challenges arising in overseas operations, uncertainties in new drug development, as well as risks related to strategic alliances with partner companies, medical cost-containment measures, generic drug products, intellectual property, possible occurrence of side effects, laws and regulations, litigation, closure or shutdown of production plants, safety and quality of raw materials, outsourcing, environmental issues, IT security and information management, financial market conditions and currency movement, internal control systems, and disasters.

This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

Contents

1. Consolidated Statement of Income	-----	1
2. Capital Expenditures, Depreciation and Amortization	-----	2
3. Segment Information	-----	2
4. Financial Results by Reporting Segment	-----	3
5. Revenue from Major Products	-----	7
6. Revenue Forecasts by Reporting Segment	-----	9
7. Consolidated Statement of Comprehensive Income	-----	10
8. Consolidated Statement of Cash Flows	-----	11
9. Consolidated Statement of Financial Position	-----	12
10. Changes in Quarterly Results	-----	14
11. Stock Information	-----	17
12. Number of Employees	-----	18
13. Major R&D Pipeline	-----	19

Currency Exchange Rates

		US (USD/JPY)	EU (EUR/JPY)	UK (GBP/JPY)	China (RMB/JPY)
FY 2014 Q2	Q2 YTD Average Rate	103.04	138.91	172.73	16.62
	Quarter End Rate	109.45	138.87	177.74	17.73
FY 2014	Yearly Average Rate	109.92	138.77	176.79	17.73
	Year End Rate	120.17	130.32	178.07	19.36
FY 2015 Q2	Q2 YTD Average Rate	121.79	135.06	187.76	19.43
	Quarter End Rate	119.96	134.97	181.86	18.96
FY 2015	Forecast Rate	120.00	137.00	183.00	19.20

* The Company discloses its consolidated financial statements according to the International Financial Reporting Standards (IFRS).

* The Group's business is comprised of pharmaceutical business and other business. The pharmaceutical business is organized into the following six reporting segments: Japan (Prescription medicines, Generics and Diagnostics), Americas (North America, Central and South America), China, Asia (mainly South Korea, Taiwan, Hong Kong, India and ASEAN), EMEA (Europe, the Middle East, Africa and Oceania) and Consumer Healthcare Business-Japan. In addition, all year-on-year figures related to segment information in this report are based on the aforementioned reporting segments.

* All amounts are rounded to the nearest specified unit.

1. Consolidated Statement of Income

(billions of yen)

	FY 2014				FY 2015				FY 2015	
	Q2 YTD	Ratio (%)	Full year	Ratio (%)		Ratio (%)				
Revenue	269.1	100.0	548.5	100.0	275.5	100.0	102.4	6.4	556.5	100.0
Cost of sales	93.8	34.9	193.6	35.3	99.5	36.1	106.1	5.7	196.0	35.2
Gross profit	175.2	65.1	354.9	64.7	176.0	63.9	100.4	0.8	360.5	64.8
Selling, general and administrative expenses	94.7	35.2	194.5	35.5	96.4	35.0	101.8	1.7	188.0	33.8
Selling expenses	35.4	13.2	70.7	12.9	31.5	11.4	89.0	(3.9)		
Personnel expenses	37.7	14.0	78.4	14.3	43.1	15.6	114.1	5.3		
Administrative and other expenses	21.6	8.0	45.4	8.3	21.8	7.9	101.2	0.3		
Research and development expenses	62.1	23.1	131.9	24.1	62.8	22.8	101.2	0.7	126.5	22.7
Other income	0.6	0.2	1.0	0.2	2.0	0.7	343.1	1.4		
Other expenses	1.0	0.4	1.1	0.2	0.6	0.2	64.0	(0.4)		
Operating profit	18.0	6.7	28.3	5.2	18.1	6.6	100.3	0.1	46.0	8.3
Financial income	0.9	0.3	2.4	0.4	1.0	0.4	107.9	0.1		
Financial costs	2.6	1.0	4.9	0.9	1.7	0.6	66.4	(0.9)		
Profit before income taxes	16.3	6.1	25.9	4.7	17.3	6.3	106.2	1.0	42.8	7.7
Income taxes	5.8	2.2	(17.6)	(3.2)	6.2	2.3	106.5	0.4		
Profit for the period	10.5	3.9	43.5	7.9	11.1	4.0	106.0	0.6	27.0	4.9
Attributable to										
Owners of the parent	10.4	3.9	43.3	7.9	11.0	4.0	105.9	0.6		
Non-controlling interests	0.1	0.0	0.2	0.0	0.1	0.0	108.4	0.0		
Comprehensive income for the period	35.7	13.3	114.2	20.8	10.2	3.7	28.7	(25.5)		
Earnings per share (EPS, yen)	36.5		151.6							
Dividends per share (DPS, yen)	70.0		150.0		70.0				150.0	
Return on equity (ROE, %)			7.7						4.5	
Dividend on equity ratio (DOE, %)			7.6						7.2	
Overseas revenue ratio (%)										

* Full year estimation for selling, general and administrative expenses includes other income and other expenses.

Notes

Revenue	Growth of Halaven, Lenvima, Fycompa and other pharmaceutical business in China, Asia and EMEA (Europe, Middle East, Africa, Oceania)
Selling, general and administrative expenses	Revenue (U.S. dollars: 1.0 billion yen, Euro: 240 million yen, U.K. pounds: 40 million yen, Chinese renminbi: 2.68 billion yen)
Other income	Operating profit (U.S. dollars: 440 million yen, Euro: 160 million yen, U.K. pounds: 90 million yen, Chinese renminbi: 880 million yen)
Financial costs	
Exchange rate effects	
Exchange rate sensitivity (annual effect of a 1 yen depreciation in currency value)	

2. Capital Expenditures, Depreciation and Amortization

(billions of yen)

	Q2 YTD	Full year	Q2 YTD	Difference	Full year (est.)
Capital expenditures	7.1	42.6	3.4	(3.7)	18.5
Property, plant and equipment	4.6	8.9	2.5	(2.1)	9.0
Intangible assets	2.5	33.6	0.9	(1.6)	9.5
Depreciation and amortization	18.7	38.9	20.5	1.8	35.0
Property, plant and equipment	6.8	13.9	6.8	(0.0)	13.5
Intangible assets	11.9	25.1	13.7	1.8	21.5

*Capital expenditures are shown on an accrual basis

3. Segment Information

1) Revenue by Reporting Segment

(billions of yen)

				CER YOY (%)	
Japan Pharmaceutical Business	139.6	278.4	134.2	96.2	96.2
Americas Pharmaceutical Business	59.9	119.8	60.6	101.1	85.7
United States	59.5	119.0	59.9	100.7	85.1
China Pharmaceutical Business	19.0	41.0	26.1	137.2	117.3
Asia Pharmaceutical Business	14.8	30.9	17.3	116.9	107.1
EMEA Pharmaceutical Business	18.1	38.5	20.2	111.4	112.8

4. Financial Results by Reporting Segment

1) Japan Pharmaceutical Business

(billions of yen)

	FY 2014		FY 2015	
	Q2 YTD	Full year	Q2 YTD	YOY (%)
Revenue	139.6	278.4	134.2	96.2
Prescription medicines	124.3	245.5	118.2	95.1
Generics	12.5	26.9	13.2	105.6
Diagnostics	2.8	6.0	2.9	101.9
Segment profit	62.7	122.4	56.8	90.5
Japan prescription medicines - revenue from major products				
Alzheimer's disease / Dementia with Lewy bodies treatment Aricept	24.2	46.9	21.5	89.0
Fully human anti-TNF- monoclonal antibody Humira	14.9	29.9	15.7	105.7
Proton-pump inhibitor Pariet	19.2	37.1	15.7	81.7
Pain treatment (neuropathic pain, fibromyalgia) Lyrica	9.8	21.5	11.8	120.7
Peripheral neuropathy treatment Methycobal	11.5	22.4	10.6	92.2
Oral anticoagulant Warfarin	4.5	8.6	3.9	88.3
Anticancer agent Halaven	3.0	6.1	3.4	115.0
Osteoporosis treatment Actonel	3.4	6.7	3.3	96.0
Insomnia treatment Lunesta	2.1	4.5	2.9	137.4
Gastritis / Gastric ulcer treatment Selbex	2.5	4.7	2.0	79.6
Anticancer agent Lenvima			0.6	

* The revenue for Pariet includes the revenue for triple formulation packs for *Helicobacter pylori* eradication, Rabecure Pack 400/800 and Rabefine Pack.

* Co-promotion income has been booked as the revenue for Lyrica.

* From the consolidated fiscal year ending March 31, 2016, the management structure for part of the costs in Japan was revised and the method for allocation of SG&A expenses changed as a result. As such, the "Japan pharmaceutical business" and "Consumer Healthcare Business - Japan" segment profits as well as "Group headquarters' management costs and other expenses" figures stated for the previous fiscal year ended March 31, 2015, have also been restated to reflect these changes. Halaven

5) EMEA Pharmaceutical Business (Europe, the Middle East, Africa and Oceania)

(billions of yen)

	FY 2014		FY 2015	
	Q2 YTD	Full year	Q2 YTD	YOY (%)
Revenue	18.1	38.5	20.2	111.4 <112.8>
Segment profit	3.1	6.6	4.4	142.6 <158.0>
EMEA - revenue from major products				
Anticancer agent Halaven	5.3	11.6	6.6	123.4 <124.4>
Antiepileptic agent Zonegran	3.9	8.1	4.1	104.6 <106.1>
Antiepileptic agent Zebinix	1.5	3.2	1.9	122.6 <125.4>
Antiepileptic agent Fycompa	1.1	2.4	1.6	146.9 <147.5>
Antiepileptic agent Inovelon	1.0	2.1	1.1	102.8 <103.2>
Anticancer agent Lenvima			0.2	

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

6) Consumer Healthcare Business Japan

(billions of yen)

	FY 2014		FY 2015	
	Q2 YTD	Full year	Q2 YTD	YOY (%)
Revenue	8.5	17.0	9.0	106.0
Segment profit	(0.0)	1.3	1.4	
Consumer Healthcare Business Japan - revenue from major products				
Vitamin B2 preparation, "Chocola BB Plus," etc. Chocola BB Group	5.6	10.3	5.6	100.9

* From the consolidated fiscal year ending March 31, 2016, the management structure for part of the costs in Japan was revised and the method for allocation of SG&A expenses changed as a result. As such, the "Japan pharmaceutical business" and "Consumer Healthcare Business—Japan" segment profits as well as "Group headquarters' management costs and other expenses" figures stated for the previous fiscal year ended March 31, 2015, have also been restated to reflect these changes.

5. Revenue from Major Products

1) Oncology-Related Products

(billions of yen)

	FY 2014		FY 2015	
	Q2 YTD	Full year	Q2 YTD	YOY (%)
Total	46.8	98.6	57.3	122.5 <109.1>
Halaven (Anticancer agent)	16.5	35.3	19.9	120.8 <112.8>
Japan	3.0	6.1	3.4	115.0
Americas	7.6	16.5	9.0	117.3 <100.5>
Asia	0.5	1.2	0.9	180.3 <162.4>
EMEA	5.3	11.6	6.6	123.4 <124.4>
Lenvima (Anticancer agent)		0.4	4.1	
Japan			0.6	
Americas		0.4	3.2	
EMEA			0.2	
Aloxi (Antiemetic agent)	23.6	49.8	27.5	116.8 <98.8>
Treakisym/Symbenda (Anticancer agent)	1.8	3.7	2.1	114.1 <113.6>
Other	4.9	9.4	3.7	76.0 <71.6>

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

2) Epilepsy Products

(billions of yen)

	FY 2014		FY 2015	
	Q2 YTD	Full year	Q2 YTD	YOY (%)
Total	14.6	31.7	18.0	123.7 <115.6>
Fycompa (Antiepileptic agent)	1.5	4.3	3.2	209.0 <193.7>
Americas	0.5	1.9	1.6	343.4 <292.8>
EMEA	1.1	2.4	1.6	146.9 <147.5>
Inovelon/Banzel (Antiepileptic agent)	5.7	12.9	7.3	128.8 <112.6>
Americas	4.5	10.4	6.1	135.0 <114.4>
EMEA	1.0	2.1	1.1	102.8 <103.2>
Zonegran (Antiepileptic agent)	5.3	10.2	5.0	93.8 <92.5>
EMEA	3.9	8.1	4.1	104.6 <106.1>
Zebinix (Antiepileptic agent)	1.5	3.2	1.9	122.6 <125.4>
Other	0.5	1.1	0.7	126.6 <126.6>

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

3) Pariet / AcipHex (Proton-pump inhibitor)

	Q2 YTD	Full year	FY 2015	
			Q2 YTD	YOY (%)
Total	29.3	56.0	23.7	81.1 <77.5>
Japan	19.2	37.1	15.7	81.7
Americas	6.7	11.7	4.3	63.7 <53.9>
China	1.3	2.9	1.8	133.9 <114.6>
Asia	1.8	3.7	1.8	99.4 <91.3>

Rabefine Pack.

4) Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)

	Q2 YTD	Full year	FY 2015	
			Q2 YTD	YOY (%)
Total	31.9	65.7	34.0	106.6 <102.1>
Japan	24.2	47.0	21.5	89.0
China	2.2	4.7	2.7	123.4 <105.5>
Asia	4.4	9.4	5.1	116.1 <106.9>

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan.

6. Revenue Forecasts by Reporting Segment (FY 2015)

(billions of yen)

	FY 2014		FY 2015	
	Q2 YTD	Full year	Q2 YTD	Full year (est.)
Japan	139.6	278.4	134.2	282.0
Prescription medicines	124.3	245.5	118.2	246.0
Alzheimer's disease / Dementia with Lewy bodies treatment				
Aricept	24.2	46.9	21.5	42.0
Fully human anti-TNF- monoclonal antibody				
Humira	14.9	29.9	15.7	34.0
Proton-pump inhibitor				
Pariet	19.2	37.1	15.7	33.0
Peripheral neuropathy treatment				
Methycobal	11.5	22.4	10.6	21.0
Anticancer agent				
Halaven	3.0	6.1	3.4	10.0
Insomnia treatment				
Lunesta	2.1	4.5	2.9	8.5
Oral anticoagulant				
Warfarin	4.5	8.6	3.9	8.0
Osteoporosis treatment				
Actonel	3.4	6.7	3.3	6.5
Gastritis / Gastric ulcer treatment				
Selbex	2.5	4.7	2.0	4.0
Generics	12.5	26.9	13.2	30.0
Diagnostics	2.8	6.0	2.9	6.0
Americas	59.9	119.8	60.6	102.0
United States	59.5	119.0	59.9	100.0
China	19.0	41.0	26.1	50.0
Asia	14.8	30.9	17.3	35.0
EMEA	18.1	38.5	20.2	45.0
Consumer Healthcare Business - Japan	8.5	17.0	9.0	17.5
Vitamin B2 preparation, "Chocola BB Plus," etc.				
Chocola BB Group	5.6	10.3	5.6	10.0
Other	9.1	22.8	8.1	25.0
Consolidated revenue	269.1	548.5	275.5	556.5
Global revenue from major products				
Aricept	31.9	65.7	34.0	61.0
Pariet/AcipHex	29.3	56.0	23.7	46.5
Halaven	16.5	35.3	19.9	47.0
Japan	3.0	6.1	3.4	10.0
Americas	7.6	16.5	9.0	19.5
Asia	0.5	1.2	0.9	1.8
EMEA	5.3	11.6	6.6	15.7
Fycopra	1.5	4.3	3.2	10.0
Americas	0.5	1.9	1.6	5.4
Asia		0.0	0.0	0.1
EMEA	1.1	2.4	1.6	4.5

8. Consolidated Statement of Cash Flows

(billions of yen)

	FY 2014	FY 2015	
	Q2 YTD	Q2 YTD	Diff.
Operating activities			
Profit before income taxes	16.3	17.3	1.0
Depreciation and amortization	18.7	20.5	1.8
Impairment losses	0.0	0.2	0.2
(Increase) decrease in working capital	6.0	13.7	7.6
Interest and dividends received	0.9	0.9	0.0
Interest paid	(2.3)	(2.3)	0.1
Income taxes paid	(6.0)	(4.8)	1.2
Income taxes refund	3.8	1.5	(2.3)
Other	(0.3)	(3.2)	(3.0)
Net cash from operating activities	37.2	43.8	6.6
Investing activities			
Purchases of property, plant and equipment (1)	(7.7)	(2.9)	4.8
Proceeds from sales of property, plant and equipment (2)	2.1	13.2	11.0
Purchases of intangible assets (3)	(2.6)	(30.8)	(28.2)
<Capital expenditures (cash basis)> (1)+(2)+(3)	(8.1)	(20.5)	(12.4)
Purchases of financial assets	(4.8)	(9.3)	(4.6)
Proceeds from sales and redemption of financial assets	5.0	9.4	4.4
Payments of time deposits exceeding 3 months	(17.3)	(13.9)	3.5
Proceeds from redemption of time deposits exceeding 3 months	12.0	20.8	8.8
Other	0.1	0.1	(0.0)
Net cash from (used in) investing activities	(13.1)	(13.4)	(0.4)
Financing activities			
Net increase (decrease) in short-term borrowings	1.5	10.3	8.8
Proceeds from long-term borrowings	74.8		(74.8)
Repayment of long-term borrowings	(85.3)		85.3
Redemption of bonds		(30.0)	(30.0)
Dividends paid	(22.8)	(22.9)	(0.0)
Other	(0.2)	0.1	0.3
Net cash from (used in) financing activities	(32.0)	(42.5)	(10.5)
Effect of exchange rate change on cash and cash equivalents	9.7	(1.1)	(10.7)
Net increase (decrease) in cash and cash equivalents	1.7	(13.2)	(14.9)
Cash and cash equivalents at beginning of year	153.9	173.3	19.4
Cash and cash equivalents at end of year	155.6	160.1	4.5
Free cash flow	29.1	23.3	(5.8)

* "Free cash flow" = "Net cash from operating activities" - "Capital expenditures (cash basis)"

Notes

Cash flow from operating activities:

Reduction in working capital based on improvement in the cash conversion cycle

Cash flow from investing activities:

Purchases of intangible assets, including sales rights, proceeds from sale of plant, property and equipment, proceeds from redemption of time deposits exceeding 3 months used for redemption of bonds

Cash flow from financing activities:

Redemption of bonds, repayment of long-term borrowings in the U.S. occurred in the same period of the previous fiscal year

9. Consolidated Statement of Financial Position

<Assets>

(billions of yen)

	March 31, 2015	Ratio (%)	September 30, 2015	Ratio (%)	% change	Diff.
Assets						
Non-current assets						
Property, plant and equipment	133.0	12.6	114.8	11.6	86.3	(18.2)
Goodwill	183.8	17.4	183.4	18.6	99.8	(0.3)
Intangible assets	127.6	12.1	114.7	11.6	89.9	(12.9)
Other financial assets	42.3	4.0	44.9	4.5	106.0	2.5
Other assets	3.4	0.3	5.3	0.5	157.2	1.9
Deferred tax assets	89.0	8.4	90.2	9.1	101.4	1.2
Total non-current assets	579.1	55.0	553.4	56.1	95.6	(25.7)
Current assets						
Inventories	87.6	8.3	81.6	8.3	93.1	(6.0)
Trade and other receivables	174.3	16.5	160.3	16.2	92.0	(14.0)
Other financial assets	28.4	2.7	21.1	2.1	74.2	(7.3)
Other assets	11.0	1.0	10.6	1.1	96.2	(0.4)
Cash and cash equivalents	173.3	16.4	160.1	16.2	92.4	(13.2)
Total current assets	474.7	45.0	433.7	43.9	91.4	(41.0)
Total assets	1,053.8	100.0	987.1	100.0	93.7	(66.7)

Notes

Assets

Decrease in property, plant and equipment due to a plant transfer in the U.S.

Decrease in trade and other receivables based on improvement in the cash conversion cycle.

Decrease in cash and cash equivalents due to redemption of bonds and payment of year-end dividends.

<Equity and Liabilities >

(billions of yen)

	March 31, 2015	Ratio (%)	September 30, 2015	Ratio (%)	% change	Diff.
Equity						
Equity attributable to owners of the parent						
Share capital	45.0	4.3	45.0	4.6	100.0	
Capital surplus	58.0	5.5	58.1	5.9	100.1	0.1
Treasury shares	(37.3)	(3.5)	(36.8)	(3.7)	98.6	0.5
Retained earnings	388.0	36.8	378.3	38.3	97.5	(9.7)
Other components of equity	145.1	13.8	142.0	14.4	97.9	(3.0)
Total equity attributable to owners of the parent	598.7	56.8	586.7	59.4	98.0	(12.1)
Non-controlling interests	3.3	0.3	3.3	0.3	100.9	0.0
Total equity	602.1	57.1	590.0	59.8	98.0	(12.1)
Liabilities						
Non-current liabilities						
Bonds and borrowings	205.8	19.5	205.8	20.8	100.0	(0.0)
Other financial liabilities	2.4	0.2	2.5	0.3	107.8	0.2
Retirement benefit liabilities	7.2	0.7	6.6	0.7	91.4	(0.6)
Provisions	1.2	0.1	1.3	0.1	109.0	0.1
Other liabilities	25.5	2.4	23.5	2.4	91.9	(2.1)
Deferred tax liabilities	0.5	0.0	0.4	0.0	69.6	(0.2)
Total non-current liabilities	242.7	23.0	240.1	24.3	98.9	(2.6)
Current liabilities						
Bonds and borrowings	30.2	2.9	10.5	1.1	34.7	(19.7)
Trade and other payables	84.6	8.0	48.4	4.9	57.3	(36.1)
Other financial liabilities	4.6	0.4	4.4	0.4	96.0	(0.2)
Income tax payables	3.9	0.4	7.4	0.7	189.9	3.5
Provisions	11.1	1.1	11.9	1.2	107.3	0.8
Other liabilities	74.6	7.1	74.3	7.5	99.6	(0.3)
Total current liabilities	209.1	19.8	157.0	15.9	75.1	(52.1)
Total liabilities	451.8	42.9	397.1	40.2	87.9	(54.7)
Total equity and liabilities	1,053.8	100.0	987.1	100.0	93.7	(66.7)

Notes

Equity

Decrease in retained earnings due to payment of year-end dividends.

Liabilities

Decrease in bonds and borrowings due to redemption of bonds.

Decrease in trade and other payables due to payment for acquisition of sales rights.

10. Changes in Quarterly Results

1) Income Statement

(billions of yen)

	FY 2014					
	Q1	Q2	Q3	Q4	Q1	Q2
Revenue	132.8	136.2	139.4	140.0	139.2	136.3
Cost of sales	48.1	45.7	49.3	50.5	49.4	50.1
Gross profit	84.7	90.5	90.1	89.5	89.8	86.2
Selling, general and administrative expenses	47.2	47.5	48.7	51.1	49.9	46.5
Selling expenses	16.8	18.6	15.6	19.7	16.0	15.5
Personnel expenses	19.3	18.4	20.4	20.3	22.8	20.3
Administrative and other expenses	11.0	10.5	12.7	11.2	11.1	10.7
Research and development expenses	29.1	33.0	35.8	34.0	32.7	30.1
Other income	0.2	0.4	0.3	0.1	0.4	1.5
Other expenses	0.1	0.9	0.1	(0.0)	0.0	0.6
Operating profit	8.5	9.6	5.8	4.5	7.6	10.5
Financial income	0.6	0.3	0.6	0.9	0.7	0.3
Financial costs	1.3	1.3	1.1	1.2	0.8	0.9
Profit before income taxes						

3) Cash Flows

(billions of yen)

	Q1	Q2	Q3	Q4	Q1	Q2
Cash flow from operating activities	7.9	29.2	4.0	34.9	21.1	22.7
Cash flow from investing activities	(4.1)	(9.0)	(13.1)	7.3	(17.4)	4.0
Cash flow from financing activities	(28.7)	(3.3)	(1.4)	(26.3)	(42.5)	(0.0)
Cash and cash equivalents at the end of period	127.1	155.6	159.2	173.3	138.7	160.1
Free cash flow	4.7	24.3	(0.5)	31.9	(10.3)	33.6

4) Financial Positions

(billions of yen)

Total assets	938.6	969.9	1,050.2	1,053.8	1,001.7	987.1
Equity	507.4	542.6	590.7	602.1	599.7	590.0
Attributable to owners of the parent	504.3	539.5	587.5	598.7	596.3	586.7
Liabilities	431.2	427.3	459.5	451.8	402.0	397.1
Bonds	30.0	30.0	30.0	30.0		
Borrowings	211.0	210.3	233.2	206.1	217.0	216.3
Ratio of equity attributable to owners of the parent (%)	53.7	55.6	55.9	56.8	59.5	59.4
Liabilities ratio (Net DER / times)	0.18	0.11	0.11	0.06	0.11	0.06

* "Liabilities ratio

5) Changes in Quarterly Revenue from Major Products

(1) Oncology-Related Products

(billions of yen)

	FY 2014				FY 2015	
	Q1	Q2	Q3	Q4	Q1	Q2
Total	24.2	22.6	25.8	26.0	28.0	29.3
Halaven (Anticancer agent)	8.2	8.3	9.3	9.5	10.1	9.8
Japan	1.6	1.4	1.6	1.5	1.8	1.6
Americas	3.8	3.8	4.3	4.5	4.4	4.6
Asia	0.2	0.3	0.3	0.4	0.4	0.5
EMEA	2.6	2.8	3.1	3.1	3.4	3.2
Lenvima (Anticancer agent)				0.4	1.3	2.8
Japan					0.2	0.4
Americas				0.4	1.1	2.2
EMEA					0.0	0.2
Aloxi (Antiemetic agent)	12.6	11.0	12.6	13.6	13.5	14.1
Treakisym/Symbenda (Anticancer agent)	1.0	0.9	1.0	0.9	1.1	1.0
Other	2.5	2.4	2.9	1.6	2.1	1.6

(2) Epilepsy Products

(billions of yen)

	FY 2014				FY 2015	
	Q1	Q2	Q3	Q4	Q1	Q2
Total	7.1	7.5	8.3	8.8	8.4	9.6
Fycompa (Antiepileptic agent)	0.7	0.8	1.1	1.6	1.5	1.8
Americas	0.2	0.3	0.4	1.0	0.7	0.9
EMEA	0.5	0.5	0.7	0.7	0.7	0.8
Inovelon/Banzel (Antiepileptic agent)	2.9	2.8	3.5	3.7	3.4	4.0
Americas	2.2	2.2	2.8	3.1	2.7	3.3
EMEA	0.5	0.5	0.6	0.5	0.5	0.5
Zonegran (Antiepileptic agent)	2.6	2.7	2.5	2.3	2.4	2.6
EMEA	1.9	1.9	2.3	2.0	2.0	2.0
Zebinix (Antiepileptic agent)	0.7	0.8	0.9	0.9	0.9	1.0
Other	0.3	0.3	0.3	0.3	0.3	0.3

(3) Pariet/AcipHex (Proton-pump inhibitor)

(billions of yen)

	FY 2014				FY 2015	
	Q1	Q2	Q3	Q4	Q1	Q2
Total	16.3	12.9	14.3	12.4	12.8	10.9
Japan	10.8	8.4	9.7	8.3	8.4	7.3
Americas	3.9	2.8	2.7	2.3	2.5	1.7
China	0.7	0.6	0.8	0.8	0.9	0.9
Asia	0.8	0.9	1.0	1.0	0.8	0.9

* The revenue from Pariet in Japan includes the sale of triple formulation packs for *Helicobacter pylori* eradication, Rabecure Pack 400/800 and Rabefine Pack.

(4) Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)

(billions of yen)

	FY 2014				FY 2015	
	Q1	Q2	Q3	Q4	Q1	Q2
Total	16.4	15.5	17.5	16.3	18.0	16.0
Japan	13.4	10.7	12.8	10.0	11.4	10.1
China	1.1	1.1	1.2	1.3	1.4	1.4
Asia	2.1	2.3	2.4	2.5	2.6	2.5

*Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan.

5) Breakdown of Shareholders by Number of Shares Held

(investors)

	March 31, 2015	Ratio (%)	September 30, 2015	Ratio (%)	Diff.
1 million or more shares	54	0.1	51	0.1	(3)
100,000 ~ 999,999 shares	152	0.2	153	0.3	1
10,000 ~ 99,999 shares	792	1.2	729	1.2	(63)
1,000 ~ 9,999 shares	12,171	18.4	10,914	18.2	(1,257)
100 ~ 999 shares	48,294	73.0	43,532	72.6	(4,762)
Less than 100 shares	4,727	7.1	4,598	7.7	(129)
Total	66,190	100.0	59,977	100.0	(6,213)

6) Breakdown by Shareholder Holding Size/Number of Shares Held

(1,000 shares)

	March 31, 2015	Ratio (%)	September 30, 2015	Ratio (%)	Diff.
1 million or more shares	189,269	63.8	195,978	66.1	6,708
100,000 ~ 999,999 shares	51,272	17.3	48,958	16.5	(2,314)
10,000 ~ 99,999 shares	19,636	6.6	18,657	6.3	(978)
1,000 ~ 9,999 shares	25,212	8.5	22,897	7.7	(2,314)
100 ~ 999 shares	11,010	3.7	9,913	3.3	(1,096)
Less than 100 shares	165	0.1	161	0.1	(4)
Total	296,566	100.0	296,566	100.0	-

* Number of shares has been rounded down to the nearest thousand.

12. Number of Employees

1) Number of Employees on Consolidated Basis

(employees)

	March 31, 2013	March 31, 2014	March 31, 2015	September 30, 2015
Total employees	10,495	10,419	10,183	9,946
Japan	5,320	5,200	4,712	4,799
Americas	1,815	1,768	1,745	1,355
China	1,454	1,559	1,607	1,657
Asia (excl. Japan, China)	1,076	1,081	1,226	1,249
EMEA	830	811	893	886

2) Number of Employees on Non-Consolidated Basis

(employees)

	March 31, 2013	March 31, 2014	March 31, 2015	September 30, 2015
Total employees (Eisai Co., Ltd.)	4,050	4,003	3,514	3,560
Production	670	642	463	462
Research and development	1,013	981	885	888
Sales, marketing and administration	2,367	2,380	2,166	2,210

* The number of total employees shown above includes staff dispatched to Eisai Co., Ltd. from other group companies, and excludes the employees of Eisai Co., Ltd. who are on loan to other group companies.

Development Code: **MORAb-003** Generic Name: **farletuzumab**

Indications / Drug class: Anticancer agent /

Development progress from April 2015 onwards Development progress from July 2015 onwards

Reference Data [R&D Pipeline] 21

October 30, 2015 / Eisai Co., Ltd.

Development Code: **MORAb-066**

Solid tumors	US: PI	In-license (Janssen Biotech)	Inj.
--------------	--------	------------------------------	------

Development Code: **E7046**

Solid tumors	US PI	In-house	Oral
--------------	-------	----------	------

(2) Neurology

Development Code: **E2020** Generic Name: **donepezil** Product Name: **Aricept**

Indications / Drug class: Treatment for Alzheimer's disease / dementia with Lewy bodies		In-house	
Description: Increases levels of the neurotransmitter acetylcholine in the brain by inhibiting the enzyme acetylcholinesterase from breaking down acetylcholine, thereby slowing the overall progression of symptoms associated with Alzheimer's disease (AD). Currently approved in more than 90 countries around the world for the treatment of mild to moderate AD. Also approved as a treatment for patients with severe AD in numerous countries including the United States, Japan, Canada, and several other Asian and Latin American countries. Approved in Japan for dementia with Lewy bodies in September 2014.			
Severe Alzheimer's disease (Additional Indication)	Study 339	CN: Submitted (February 2015)	Oral
Regression symptoms in people with Down syndrome (Additional Indication)	345	JP: PII	Oral
Transdermal formulation (E2022, Additional Formulation)		JP: PI (Collaboration with Teikoku Pharmaceuticals)	Patch

Development Code: **E2007** Generic Name: **perampanel** Product Name: **Fycompa**

Indications / Drug class: Antiepileptic agent / AMPA receptor antagonist		In-house	
Description: A selective antagonist against the AMPA receptor (a glutamate receptor subtype). Approved as an adjunctive therapy for partial-onset seizures in 45 countries including in Europe, the United States, and Asia. Also approved as an adjunctive therapy for primary generalized tonic-clonic seizures in the United States and Europe.			
Partial-onset seizures	Study 335	JP: submitted (July 2015)	Oral
Primary generalized tonic-clonic seizures (Additional Indication)	332	US: approved (June 2015) EU: approved (June 2015) JP: submitted (July 2015)	Oral
Oral suspension (Additional Formulation)		US/EU: submitted (June 2015), accepted (September 2015)	Oral
Pediatric partial-onset seizures (Additional Indication)	232	US/EU: PII	Oral

In Japan, an application covering both partial onset and primary generalized tonic-clonic seizures was submitted.

Development Code: **E0302** Generic Name: **mecobalamin**

Indications / Drug class: Amyotrophic lateral sclerosis (ALS)		In-house	
Description: Mecobalamin (vitamin B ₁₂ coenzyme) is widely used for the treatment of peripheral neuropathy. An ultra-high dose of mecobalamin (50-100 times the approved dose) is currently being investigated as a potential treatment for amyotrophic lateral sclerosis (ALS).			
Amyotrophic lateral sclerosis (ALS)	Study 761/762	JP: submitted (May 2015)	Inj.

Development progress from April 2015 onwards Development progress from July 2015 onwards

Development Code: **BAN2401**

Indications / Drug class: Anti-Alzheimer's agent / humanized anti-A β protofibrils monoclonal antibody		In-license (BioArctic Neuroscience)	
Description: A humanized IgG1 monoclonal antibody that targets amyloid beta (A β) protofibrils. Expected to be effective in the treatment of Alzheimer's disease by halting disease progression through the elimination of neurotoxic A β protofibrils.			
Alzheimer's disease	Study 201	JP/US/EU: PII	Inj.

Japan has also been added to the global Phase II study

Development Code: **E2006** Generic Name: **lemborexant**

Indications / Drug class: Anti-insomnia agent / orexin receptor antagonist		In-house	
Description: Anti-insomnia agent with novel mechanism of action. By antagonizing the orexin receptors that maintain wakefulness, it is expected to alleviate wakefulness and thereby induce natural sleep.			
Insomnia	Study 201	US: PII	Oral

Development Code: **E2609**

Indications / Drug class: Anti-Alzheimer's agent / beta secretase cleaving enzyme (BACE) inhibitor		In-house	
Description: BACE inhibitor. By inhibiting beta-site amyloid precursor protein cleaving enzymes (BACE), the agent reduces the amount of amyloid beta in the brain, potentially improving symptoms and slowing the progression of Alzheimer's disease.			
Alzheimer's disease	Study 202	US: PII	Oral

Development Code: **APD356** Generic Name: **lorcaserin** Product Name: **BELVIQ**

Indications / Drug class: Anti-obesity agent / serotonin 2C receptor agonist		In-license (Arena Pharmaceuticals)	
Description: Anti-obesity agent with novel mechanism of action. By selectively activating serotonin 2C receptors in the brain, it is believed to decrease food consumption and promote satiety. Approved in the United States by the U.S Food and Drug Administration on 8/16/10.			

(3) Other (Gastrointestinal, Blood and Immunological Disorders)

Development Code: **E3810** Generic Name: **rabeprazole** Product Name: **Pariet/AcipHex**

Indications / Drug class: Proton pump inhibitor		In-house		
Description: A proton pump inhibitor approved for the treatment of gastric and duodenal ulcers, reflux esophagitis, eradication of <i>Helicobacter pylori</i> infections and triple formulation packs (combination packs) for <i>H. pylori</i> eradication that include rabeprazole. Approved for the prevention of recurrent gastric or duodenal ulcer caused by low-dose aspirin therapy as well as 5 mg tablet formulation in December 2014.				
Maintenance therapy for proton pump inhibitor (PPI)-resistant reflux esophagitis (Additional Indication)	Study 311	JP: PIII	Submission Target: FY2016	Oral
Functional dyspepsia (Additional Indication)	204	JP: PII		Oral

Development Code: **E5501/AKR-501** Generic Name: **avatrombopag**

Indications / Drug class: Treatment for thrombocytopenia / thrombopoietin receptor agonist		In-house		
Description: A novel, oral thrombopoietin receptor agonist that stimulates platelet production. Expected to show effects against conditions that are associated with thrombocytopenia.				
Thrombocyt				

Development progress from April 2015 onwards Development progress from July 2015 onwards